BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 22902917)

  • 21. Clinical impact of FDG-PET imaging in post-therapy surveillance of uterine cervical cancer: from diagnosis to prognosis.
    Chung HH; Kim SK; Kim TH; Lee S; Kang KW; Kim JY; Park SY
    Gynecol Oncol; 2006 Oct; 103(1):165-70. PubMed ID: 16574205
    [TBL] [Abstract][Full Text] [Related]  

  • 22. 18-F-fluorodeoxyglucose-positron emission tomography evaluation of early metabolic response during radiation therapy for cervical cancer.
    Schwarz JK; Lin LL; Siegel BA; Miller TR; Grigsby PW
    Int J Radiat Oncol Biol Phys; 2008 Dec; 72(5):1502-7. PubMed ID: 18538498
    [TBL] [Abstract][Full Text] [Related]  

  • 23. 18F-FDG PET/CT can predict nodal metastases but not recurrence in early stage uterine cervical cancer.
    Crivellaro C; Signorelli M; Guerra L; De Ponti E; Buda A; Dolci C; Pirovano C; Todde S; Fruscio R; Messa C
    Gynecol Oncol; 2012 Oct; 127(1):131-5. PubMed ID: 22772064
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-Term Outcomes of Cervical Cancer Patients Treated With Definitive Chemoradiation Following a Complete Metabolic Response.
    Lin AJ; Dehdashti F; Massad LS; Thaker PH; Powell MA; Mutch DG; Schwarz JK; Markovina S; Siegel BA; Grigsby PW
    Clin Oncol (R Coll Radiol); 2021 May; 33(5):300-306. PubMed ID: 33581976
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Volumetric assessment of apparent diffusion coefficient predicts outcome following chemoradiation for cervical cancer.
    Ho JC; Fang P; Cardenas CE; Mohamed ASR; Fuller CD; Allen PK; Bhosale PR; Frumovitz MM; Jhingran A; Klopp AH
    Radiother Oncol; 2019 Jun; 135():58-64. PubMed ID: 31015171
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Findings on 18F-FDG PET scans after neoadjuvant chemoradiation provides prognostic stratification in patients with locally advanced rectal carcinoma subsequently treated by radical surgery.
    Kalff V; Duong C; Drummond EG; Matthews JP; Hicks RJ
    J Nucl Med; 2006 Jan; 47(1):14-22. PubMed ID: 16391182
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Positron emission tomography scan for predicting clinical outcome of patients with recurrent cervical carcinoma following radiation therapy.
    Sharma DN; Rath GK; Kumar R; Malhotra A; Kumar S; Pandjatcharam J; Maharjan S
    J Cancer Res Ther; 2012; 8(1):23-7. PubMed ID: 22531509
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Preoperative hyperfractionated chemoradiation for locally recurrent rectal cancer in patients previously irradiated to the pelvis: A multicentric phase II study.
    Valentini V; Morganti AG; Gambacorta MA; Mohiuddin M; Doglietto GB; Coco C; De Paoli A; Rossi C; Di Russo A; Valvo F; Bolzicco G; Dalla Palma M;
    Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1129-39. PubMed ID: 16414206
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Outcome of cervical carcinoma with locoregional lymph node involvement by FDG-PET].
    Paumier A; Blanchard P; Mazeron R; Dumas I; Morice P; Lhomme C; Leboulleux S; Haie-Meder C
    Cancer Radiother; 2012 May; 16(3):183-9. PubMed ID: 22387194
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical usefulness of ¹⁸F-fluorodeoxyglucose-positron emission tomography in patients with locally advanced pancreatic cancer planned to undergo concurrent chemoradiation therapy.
    Chang JS; Choi SH; Lee Y; Kim KH; Park JY; Song SY; Cho A; Yun M; Lee JD; Seong J
    Int J Radiat Oncol Biol Phys; 2014 Sep; 90(1):126-33. PubMed ID: 25015206
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clarifying the diagnosis of clinically suspected recurrence of cervical cancer: impact of 18F-FDG PET.
    van der Veldt AA; Buist MR; van Baal MW; Comans EF; Hoekstra OS; Molthoff CF
    J Nucl Med; 2008 Dec; 49(12):1936-43. PubMed ID: 18997039
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognostic factors for local and distant recurrence in stage I and II cervical carcinoma.
    Werner-Wasik M; Schmid CH; Bornstein L; Ball HG; Smith DM; Madoc-Jones H
    Int J Radiat Oncol Biol Phys; 1995 Jul; 32(5):1309-17. PubMed ID: 7635770
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Metabolic (FDG-PET) response after radical radiotherapy/chemoradiotherapy for non-small cell lung cancer correlates with patterns of failure.
    Mac Manus MP; Hicks RJ; Matthews JP; Wirth A; Rischin D; Ball DL
    Lung Cancer; 2005 Jul; 49(1):95-108. PubMed ID: 15949595
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [(18)F]FDG-PET standard uptake value as a metabolic predictor of bone marrow response to radiation: impact on acute and late hematological toxicity in cervical cancer patients treated with chemoradiation therapy.
    Elicin O; Callaway S; Prior JO; Bourhis J; Ozsahin M; Herrera FG
    Int J Radiat Oncol Biol Phys; 2014 Dec; 90(5):1099-107. PubMed ID: 25442041
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic value of 18F-fluorodeoxyglucose uptake in pelvic lymph nodes in patients with cervical cancer treated with definitive chemoradiotherapy.
    Onal C; Guler OC; Reyhan M; Yapar AF
    Gynecol Oncol; 2015 Apr; 137(1):40-6. PubMed ID: 25641567
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Stage IB2, IIA and IIB cervical carcinoma without lymph node extension treated with neoadjuvant chemoradiotherapy].
    Monnier L; Touboul E; Daraï E; Lefranc JP; Lauratet B; Ballester M; Huguet F
    Bull Cancer; 2016 Feb; 103(2):164-72. PubMed ID: 26822905
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Predicting tumor recurrence in patients with cervical carcinoma treated with definitive chemoradiotherapy: value of quantitative histogram analysis on diffusion-weighted MR images.
    Erbay G; Onal C; Karadeli E; Guler OC; Arica S; Koc Z
    Acta Radiol; 2017 Apr; 58(4):481-488. PubMed ID: 27445314
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prospective multi-institutional study of definitive radiotherapy with high-dose-rate intracavitary brachytherapy in patients with nonbulky (<4-cm) stage I and II uterine cervical cancer (JAROG0401/JROSG04-2).
    Toita T; Kato S; Niibe Y; Ohno T; Kazumoto T; Kodaira T; Kataoka M; Shikama N; Kenjo M; Tokumaru S; Yamauchi C; Suzuki O; Sakurai H; Numasaki H; Teshima T; Oguchi M; Kagami Y; Nakano T; Hiraoka M; Mitsuhashi N
    Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):e49-56. PubMed ID: 21470794
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Risk assessment model for overall survival in patients with locally advanced cervical cancer treated with definitive concurrent chemoradiotherapy.
    Shim SH; Lee SW; Park JY; Kim YS; Kim DY; Kim JH; Kim YM; Kim YT; Nam JH
    Gynecol Oncol; 2013 Jan; 128(1):54-59. PubMed ID: 23063760
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical utility of F-18 FDG PET/CT in recurrent breast carcinoma.
    Manohar K; Mittal BR; Senthil R; Kashyap R; Bhattacharya A; Singh G
    Nucl Med Commun; 2012 Jun; 33(6):591-6. PubMed ID: 22334135
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.